AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.
Business & Industry
- Imfinzi is the first immunotherapy to demonstrate significant overall survival benefit in unresectable, Stage III lung cancer
- The Merck Accelerator Program 2019
- Novo Nordisk announces plans to transform its approach to Research & Development
- World's largest Alzheimer's survey reveals most adults believe a cure will be developed in their lifetime
- The Lancet Respiratory Medicine publishes first Phase III trial for PT010 triple combination therapy in moderate to very severe chronic obstructive pulmonary disease
Research & Development
- DNA islands effective as 'anti-bacterial drones'
- Pre-clinical success for a universal flu vaccine offers hope for third generation approach
- Discovery could explain failed clinical trials for Alzheimer's, and provide a solution
- Aspirin found not to prolong healthy aging
- Clinical gene discovery program solves 30 medical mysteries
- Dietary fiber reduces brain inflammation during aging
- Drug for pancreatic cancer developed by college of pharmacy researchers
Conferences & Events
- Social Media in the Pharmaceutical Industry Conference 2019
- Lyophilization USA Conference 2018
- SMi presents the 13th annual industry leading conference: Cold Chain Distribution
- Orphan Drugs and Rare Diseases Conference 2018
- Immuno-Oncology Conference 2018
- Ophthalmic Drugs Conference 2018
- SMi presents the launch of Cell & Gene Therapy 2018
Regulatory Affairs
- FDA awards 12 grants to fund new clinical trials to advance the development of medical products for the treatment of rare diseases
- FDA approves new kind of treatment for hairy cell leukemia
- FDA approves first-of-its kind targeted RNA-based therapy to treat a rare disease
- FDA approves treatment for two rare types of non-Hodgkin lymphoma
- FDA approves first targeted treatment for patients with relapsed or refractory acute myeloid leukemia who have a certain genetic mutation